The Judicial Panel for Multidistrict Litigation transferred all existing Invokana (canagliflozin) and Invokamet (canagliflozin/metformin) cases alleging ketoacidosis and kidney disease from federal courts across the country to the United States District Court for the District of New Jersey on December 7, 2016. A total of 55 cases alleging injuries from these diabetes drugs were transferred from Illinois, Kentucky, Minnesota, Missouri, Virginia and West Virginia to a consolidated docket before the Honorable Brian R. Martinotti.

Invokana and Invokamet are classified as sodium-glucose-cotransporter-2 drugs (a/k/a SGLT2 inhibitors). SGLT2s work by preventing the kidneys from reabsorbing blood sugar. This lets the sugar leave the body through the urine, and thereby lowers blood glucose levels. SGLT2s are prescribed for Type 2 diabetes.… Read More


Posted by Marilyn McGoldrick on Nov 17, 2014 12:37:28 PM   Four women were awarded $26.7 million in compensatory damages in the first federal bellwether trial over Boston Scientific Corp.’s Pinnacle transvaginal mesh implants. The jury ruled that the mesh implants were defectively designed, and that Boston Scientific Corp. had failed to warn doctors and… Read More


Takeda Pharmaceuticals, the maker of diabetes drug Actos (generic name pioglitazone), intentionally destroyed and deleted key documents that would have helped plaintiffs in their bladder cancer lawsuits pending against the company, according to the federal judge overseeing the litigation. Judge Rebecca Doherty ruled that Takeda destroyed relevant documents, intentionally deleted documents in bad faith with knowledge of its legal duty to preserve them, and the absence of those documents was and is prejudicial to plaintiffs.… Read More


Posted by Marilyn McGoldrick on Jun 12, 2014 11:51:51 AM You may have heard a radio or television advertisement targeting men concerning a condition known as “Low T” – shorthand for low testosterone.  The ads sell testosterone replacement therapies as a way of combating “Low T.”  The ads list “symptoms” of the condition that commonly… Read More


On August 15, 2013, a West Virginia jury awarded Donna Cisson a $2 million verdict, $250,000 in compensatory damages and $1.75 million in punitive damages, against C. R. Bard for injuries caused by its transvaginal mesh implant Avaulta. Donna Cisson’s attorneys presented evidence that her vaginal mesh implant caused bleeding, constant intractable pain and bladder spasms. Ultimately Cisson endured several surgeries to remove much of the surgical mesh; she still has 22 inches of mesh inside her body and the constant pain.… Read More


Posted by Marilyn McGoldrick on Jul 1, 2013 4:06:00 PM Newly-unsealed confidential records show that C.R. Bard, Inc., knowingly ignored a part supplier’s direct warning that the plastic Bard was supplied with was unsuitable for human implantation. The revelation about Bard’s behavior comes as the surgical mesh manufacturer is embroiled in litigation over its defective… Read More


Posted by Marilyn McGoldrick on Jun 17, 2013 3:03:00 PM On June 12, 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) transferred more than 39 Stryker Rejuvenate and ABGII defective hip cases to the U.S. District Court of Minnesota. The MDL was approved to allow for coordination of pretrial discovery and to preserve judicial… Read More